Condition: Neutropenia · Sponsor: X4 Pharmaceuticals
The purpose of this study is to demonstrate the efficacy and evaluate the safety and tolerability of mavorixafor in participants with congenital or acquired primary autoimmune and idiopathic chronic neutropenic disorders who are experiencing recurrent and/or serious infections as assessed by demonstrating its clinical benefit and increasing levels of circulating neutrophils.
This description comes directly from the study's public registry record.
Patient Affairs and Advocacy · 857-529-5779 · clinicaltrialinfo@x4pharma.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| UC Irvine | Irvine, California, United States | Recruiting |
| Orso Health | La Jolla, California, United States | Recruiting |
| University of California, Los Angeles-UCLA | Los Angeles, California, United States | Recruiting |
| Orso Health | Torrance, California, United States | Recruiting |
| University of Southern Florida | St. Petersburg, Florida, United States | Recruiting |
| Children's Healthcare of Atlanta (CHOA) | Atlanta, Georgia, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Boston Children's Cancer Center | Boston, Massachusetts, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| Duke University Medical Center | Durham, North Carolina, United States | Recruiting |
+ 102 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06056297